Stereotactic body radiation therapy (SBRT) for prostate cancer: Improving treatment delivery efficiency and accuracy
-
Published:2024-06
Issue:
Volume:30
Page:100253
-
ISSN:2405-6324
-
Container-title:Technical Innovations & Patient Support in Radiation Oncology
-
language:en
-
Short-container-title:Technical Innovations & Patient Support in Radiation Oncology
Author:
Mastella EdoardoORCID,
Epile Joel E.,
De Guglielmo Eleonora,
Fabbri Sara,
Calderoni FrancescaORCID,
Manco Luigi,
Szilagyi Klarisa E.,
Malorgio Antonio,
Turra Alessandro,
Stefanelli Antonio
Reference43 articles.
1. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics;Proust-Lima;Int J Radiat Oncol Biol Phys,2011
2. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy;Miralbell;Int J Radiat Oncol Biol Phys,2012
3. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial;Tree;Lancet Oncol,2022
4. The association between acute and late genitourinary and gastrointestinal toxicities: an analysis of the PACE B study;Ratnakumaran;Cancers (Basel),2023
5. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献